Halozyme Therapeutics Director James M. Daly Receives Annual Equity Grants

Summary of Transaction

On October 1, 2026, James M. Daly, a Director of Halozyme Therapeutics, Inc. ($HALO), was granted equity awards under the issuer's director compensation program. The filing details two awards:

1. Restricted Stock Units (Table I):

   • Shares Acquired: 1,169 RSUs
   • Transaction Price: $0.00
   • Post-Transaction Holdings: 1,169 RSUs
   • Vesting Terms: Vests on the date of the Issuer's 2027 annual meeting of stockholders.

2. Option to Purchase Common Stock (Table II):

   • Derivative Securities Acquired: 1,775 stock options
   • Exercise Price: $106.94 per share
   • Expiration Date: October 1, 2036
   • Vesting Terms: Vests in full on the date of the Issuer's 2027 annual meeting of stockholders.

Market Sentiment & Significance

• Trading Significance: Low
• Context: These transactions reflect routine, non-discretionary equity compensation for board service rather than an open-market purchase or sale. Because no open-market purchase was made and no cash changed hands, the filings have minimal predictive value regarding future stock performance.